Login to Your Account

Neurocrine, Abbott in $575M Endometriosis Pain Drug Deal

By Donna Young

Thursday, June 17, 2010
Neurocrine Biosciences Inc.'s investors were revved up Wednesday on the news that the firm had inked an exclusive worldwide deal potentially worth more than $575 million, including $75 million up front, with Abbott to develop and commercialize elagolix, a first-in-class oral gonadotropin-releasing hormone antagonist (GnRH), for the treatment of endometriosis-related pain. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription